Skip to main content
Top
Published in: BMC Gastroenterology 1/2013

Open Access 01-12-2013 | Research article

High mortality of pneumonia in cirrhotic patients with ascites

Authors: Tsung-Hsing Hung, Chih-Wei Tseng, Yu-Hsi Hsieh, Kuo-Chih Tseng, Chih-Chun Tsai, Chen-Chi Tsai

Published in: BMC Gastroenterology | Issue 1/2013

Login to get access

Abstract

Background

Cirrhotic patients with ascites are prone to develop various infectious diseases. This study aimed to evaluate the occurrence and effect of major infectious diseases on the mortality of cirrhotic patients with ascites.

Methods

We reviewed de-identified patient data from the National Health Insurance Database, derived from the Taiwan National Health Insurance Program, to enroll 4,576 cirrhotic patients with ascites, who were discharged from Taiwan hospitals between January 1, 2004 and June 30, 2004. We collected patients’ demographic and clinical data, and reviewed diagnostic codes to determine infectious diseases and comorbid disorders of their hospitalizations. Patients were divided into an infection group and non-infection group and hazard ratios (HR) were determined for specific infectious diseases.

Results

Of the total 4,576 cirrhotic patients with ascites, 1,294 (28.2%) were diagnosed with infectious diseases during hospitalization. The major infectious diseases were spontaneous bacterial peritonitis (SBP) (645, 49.8%), urinary tract infection (151, 11.7%), and pneumonia (100, 7.7%). After adjusting for patients’ age, gender, and other comorbid disorders, the HRs of infectious diseases for 30-day and 90-day mortality of cirrhotic patients with ascites were 1.81 (1.54-2.11) and 1.60 (1.43-1.80) respectively, compared to those in the non-infection group. The adjusted HRs of pneumonia, urinary tract infection (UTI), spontaneous bacterial peritonitis (SBP), and sepsis without specific focus (SWSF) were 2.95 (2.05-4.25), 1.32 (0.86-2.05), 1.77 (1.45-2.17), and 2.19 (1.62-2.96) for 30-day mortality, and 2.57 (1.93-3.42), 1.36 (1.01-1.82), 1.51 (1.29-1.75), and 2.13 (1.70-2.66) for 90-day mortality, compared to those in the non-infection group.

Conclusion

Infectious diseases increased 30-day and 90-day mortality of cirrhotic patients with ascites. Among all infectious diseases identified, pneumonia carried the highest risk for mortality.
Appendix
Available only for authorised users
Literature
1.
go back to reference Christou L, Pappas G, Falagas ME: Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol. 2007, 102: 1510-1517. 10.1111/j.1572-0241.2007.01286.x.CrossRefPubMed Christou L, Pappas G, Falagas ME: Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol. 2007, 102: 1510-1517. 10.1111/j.1572-0241.2007.01286.x.CrossRefPubMed
2.
go back to reference Bonnel AR, Bunchorntavakul C, Reddy KR: Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011, 9: 727-738. 10.1016/j.cgh.2011.02.031.CrossRefPubMed Bonnel AR, Bunchorntavakul C, Reddy KR: Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011, 9: 727-738. 10.1016/j.cgh.2011.02.031.CrossRefPubMed
3.
go back to reference Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J: Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002, 35: 140-148. 10.1053/jhep.2002.30082.CrossRefPubMed Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J: Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002, 35: 140-148. 10.1053/jhep.2002.30082.CrossRefPubMed
4.
go back to reference Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, Colloredo-Mels G, Corigliano P, Fornaciari G, Marenco G, Pistarà R, Salvagnini M, Sangiovanni A: Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001, 33: 41-48. 10.1016/S1590-8658(01)80134-1.CrossRefPubMed Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, Colloredo-Mels G, Corigliano P, Fornaciari G, Marenco G, Pistarà R, Salvagnini M, Sangiovanni A: Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001, 33: 41-48. 10.1016/S1590-8658(01)80134-1.CrossRefPubMed
5.
go back to reference Caly WR, Strauss E: A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993, 18: 353-358. 10.1016/S0168-8278(05)80280-6.CrossRefPubMed Caly WR, Strauss E: A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993, 18: 353-358. 10.1016/S0168-8278(05)80280-6.CrossRefPubMed
6.
go back to reference Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Plequezuelo M, Burroughs AK: Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010, 139: 1246-1256. 10.1053/j.gastro.2010.06.019.CrossRefPubMed Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Plequezuelo M, Burroughs AK: Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010, 139: 1246-1256. 10.1053/j.gastro.2010.06.019.CrossRefPubMed
7.
go back to reference Runyon BA: Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology. 1986, 91: 1343-1346.CrossRefPubMed Runyon BA: Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology. 1986, 91: 1343-1346.CrossRefPubMed
8.
go back to reference Pinzello G, Simonetti RG, Craxi A, Di Piazza S, Spanò C, Pagliaro L: Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology. 1983, 3: 545-549.PubMed Pinzello G, Simonetti RG, Craxi A, Di Piazza S, Spanò C, Pagliaro L: Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology. 1983, 3: 545-549.PubMed
9.
go back to reference Tandon P, Garcia-Tsao G: Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008, 28: 26-42. 10.1055/s-2008-1040319.CrossRefPubMed Tandon P, Garcia-Tsao G: Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008, 28: 26-42. 10.1055/s-2008-1040319.CrossRefPubMed
10.
go back to reference Tandon P, Garcia-Tsao G: Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 2011, 9: 260-265. 10.1016/j.cgh.2010.11.038.CrossRefPubMed Tandon P, Garcia-Tsao G: Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 2011, 9: 260-265. 10.1016/j.cgh.2010.11.038.CrossRefPubMed
11.
go back to reference Viasus D, Garcia-Vidal C, Castellote J, Adamuz J, Verdaquer R, Dorca J, Manresa F, Gudio F, Carratalà J: Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine. 2011, 90: 110-118. 10.1097/MD.0b013e318210504c.CrossRefPubMed Viasus D, Garcia-Vidal C, Castellote J, Adamuz J, Verdaquer R, Dorca J, Manresa F, Gudio F, Carratalà J: Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine. 2011, 90: 110-118. 10.1097/MD.0b013e318210504c.CrossRefPubMed
12.
go back to reference Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT: Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009, 137: 1641-1648. 10.1053/j.gastro.2009.07.060.CrossRefPubMed Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT: Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009, 137: 1641-1648. 10.1053/j.gastro.2009.07.060.CrossRefPubMed
13.
go back to reference Hung TH, Hsieh YH, Tsai CC, Tseng KC, Tsai CC: Is liver cirrhosis a risk factor for osteonecrosis of the femoral head in adults? A population-based 3-year follow-up study. Intern Med. 2011, 50: 2563-2568. 10.2169/internalmedicine.50.5952.CrossRefPubMed Hung TH, Hsieh YH, Tsai CC, Tseng KC, Tsai CC: Is liver cirrhosis a risk factor for osteonecrosis of the femoral head in adults? A population-based 3-year follow-up study. Intern Med. 2011, 50: 2563-2568. 10.2169/internalmedicine.50.5952.CrossRefPubMed
14.
go back to reference Hung TH, Tsai CC, Hsieh YH, Tsai CC, Tseng CW, Tsai JJ: Effect of renal impairment on mortality of patients with cirrhosis and spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 2012, 10: 677-681. 10.1016/j.cgh.2012.02.026.CrossRefPubMed Hung TH, Tsai CC, Hsieh YH, Tsai CC, Tseng CW, Tsai JJ: Effect of renal impairment on mortality of patients with cirrhosis and spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 2012, 10: 677-681. 10.1016/j.cgh.2012.02.026.CrossRefPubMed
15.
go back to reference Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003, 348: 1546-1554. 10.1056/NEJMoa022139.CrossRefPubMed Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003, 348: 1546-1554. 10.1056/NEJMoa022139.CrossRefPubMed
16.
go back to reference Thuluvath PJ, Morss S, Thompson R: Spontaneous bacterial peritonitis–in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol. 2001, 96: 1232-1236.PubMed Thuluvath PJ, Morss S, Thompson R: Spontaneous bacterial peritonitis–in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol. 2001, 96: 1232-1236.PubMed
17.
go back to reference Ko CW, Kelley K, Meyer KE: Physician specialty and the outcomes and cost of admissions for end-stage liver disease. Am J Gastroenterol. 2001, 96: 3411-3418. 10.1111/j.1572-0241.2001.05343.x.CrossRefPubMed Ko CW, Kelley K, Meyer KE: Physician specialty and the outcomes and cost of admissions for end-stage liver disease. Am J Gastroenterol. 2001, 96: 3411-3418. 10.1111/j.1572-0241.2001.05343.x.CrossRefPubMed
18.
go back to reference Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT: Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut. 2011, 60: 1038-1042. 10.1136/gut.2010.224329.CrossRefPubMed Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT: Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut. 2011, 60: 1038-1042. 10.1136/gut.2010.224329.CrossRefPubMed
19.
go back to reference Kang CI, Song JH, Ko KS, Chung DR, Peck KR, Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group: Clinical significance of Staphylococcus aureus infection in patients with chronic liver diseases. Liver Int. 2010, 30: 1333-1338. 10.1111/j.1478-3231.2010.02270.x.CrossRefPubMed Kang CI, Song JH, Ko KS, Chung DR, Peck KR, Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group: Clinical significance of Staphylococcus aureus infection in patients with chronic liver diseases. Liver Int. 2010, 30: 1333-1338. 10.1111/j.1478-3231.2010.02270.x.CrossRefPubMed
20.
go back to reference Cheruvattath R, Balan V: Infections in patients with end-stage liver disease. J Clin Gastroenterol. 2007, 41: 403-411. 10.1097/01.mcg.0000248018.08515.f9.CrossRefPubMed Cheruvattath R, Balan V: Infections in patients with end-stage liver disease. J Clin Gastroenterol. 2007, 41: 403-411. 10.1097/01.mcg.0000248018.08515.f9.CrossRefPubMed
21.
go back to reference Propst-Graham KL, Preheim LC, Vander Top EA, Snitily MU, Gentry-Nielsen MJ: Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumoniae. BMC Microbiol. 2007, 7: 94-10.1186/1471-2180-7-94.CrossRefPubMedPubMedCentral Propst-Graham KL, Preheim LC, Vander Top EA, Snitily MU, Gentry-Nielsen MJ: Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumoniae. BMC Microbiol. 2007, 7: 94-10.1186/1471-2180-7-94.CrossRefPubMedPubMedCentral
22.
go back to reference Ono Y, Watanabe T, Matsumoto K, Ito T, Kunii O, Goldstein E: Opsonophagocytic dysfunction in patients with liver cirrhosis and low responses to tumor necrosis factor-alpha and lipopolysaccharide in patients’ blood. J Infect Chemother. 2004, 10: 200-207.CrossRefPubMed Ono Y, Watanabe T, Matsumoto K, Ito T, Kunii O, Goldstein E: Opsonophagocytic dysfunction in patients with liver cirrhosis and low responses to tumor necrosis factor-alpha and lipopolysaccharide in patients’ blood. J Infect Chemother. 2004, 10: 200-207.CrossRefPubMed
23.
go back to reference Eddens T, Kolls JK: Host defenses against bacterial lower respiratory tract infection. Curr Opin Immunol. 2012, 24: 424-430. 10.1016/j.coi.2012.07.005.CrossRefPubMedPubMedCentral Eddens T, Kolls JK: Host defenses against bacterial lower respiratory tract infection. Curr Opin Immunol. 2012, 24: 424-430. 10.1016/j.coi.2012.07.005.CrossRefPubMedPubMedCentral
24.
go back to reference Gentry MJ, Snitily MU, Preheim LC: Phagocytosis of Streptococcus pneumonia measured in vitro and in vivo in a rat model of carbon tetrachloride-induced liver cirrhosis. J Infect Dis. 1995, 171: 350-355. 10.1093/infdis/171.2.350.CrossRefPubMed Gentry MJ, Snitily MU, Preheim LC: Phagocytosis of Streptococcus pneumonia measured in vitro and in vivo in a rat model of carbon tetrachloride-induced liver cirrhosis. J Infect Dis. 1995, 171: 350-355. 10.1093/infdis/171.2.350.CrossRefPubMed
25.
go back to reference Mueller-Ortiz SL, Drouin SM, Wetsel RA: The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect Immun. 2004, 72: 2899-2906. 10.1128/IAI.72.5.2899-2906.2004.CrossRefPubMedPubMedCentral Mueller-Ortiz SL, Drouin SM, Wetsel RA: The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect Immun. 2004, 72: 2899-2906. 10.1128/IAI.72.5.2899-2906.2004.CrossRefPubMedPubMedCentral
26.
go back to reference Duchini A, Viernes ME, Nyberg LM, Hendry RM, Pockros PJ: Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med. 2000, 160: 113-115. 10.1001/archinte.160.1.113.CrossRefPubMed Duchini A, Viernes ME, Nyberg LM, Hendry RM, Pockros PJ: Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med. 2000, 160: 113-115. 10.1001/archinte.160.1.113.CrossRefPubMed
27.
go back to reference Marzano A, Marengo A, Ruggiero T, Allice T, Sanna C, Alessandria C, Morgando A, Sciandrello MC, Franzin AM, Rizzetto M, Ghisetti V: Clinical impact of A/H1/N1/09 influenza in patients with cirrhosis: experience from a nosocomial cluster of infection. J Med Virol. 2013, 85: 1-7. 10.1002/jmv.23454.CrossRefPubMed Marzano A, Marengo A, Ruggiero T, Allice T, Sanna C, Alessandria C, Morgando A, Sciandrello MC, Franzin AM, Rizzetto M, Ghisetti V: Clinical impact of A/H1/N1/09 influenza in patients with cirrhosis: experience from a nosocomial cluster of infection. J Med Virol. 2013, 85: 1-7. 10.1002/jmv.23454.CrossRefPubMed
28.
go back to reference Benson AB, Burton JR, Austin GL, Biggins SW, Zimmerman MA, Kam I, Mandell S, Silliman CC, Rosen H, Moss M: Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl. 2011, 17: 149-158. 10.1002/lt.22212.CrossRefPubMedPubMedCentral Benson AB, Burton JR, Austin GL, Biggins SW, Zimmerman MA, Kam I, Mandell S, Silliman CC, Rosen H, Moss M: Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl. 2011, 17: 149-158. 10.1002/lt.22212.CrossRefPubMedPubMedCentral
29.
go back to reference D’Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006, 44: 217-231. 10.1016/j.jhep.2005.10.013.CrossRefPubMed D’Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006, 44: 217-231. 10.1016/j.jhep.2005.10.013.CrossRefPubMed
30.
go back to reference Abdel-Khalek EE, El-Fakhry A, Helaly M, Hamed M, Elbaz O: Systemic inflammatory response syndrome in patients with liver cirrhosis. Arab J Gastroenterol. 2011, 12: 173-177. 10.1016/j.ajg.2011.11.006.CrossRefPubMed Abdel-Khalek EE, El-Fakhry A, Helaly M, Hamed M, Elbaz O: Systemic inflammatory response syndrome in patients with liver cirrhosis. Arab J Gastroenterol. 2011, 12: 173-177. 10.1016/j.ajg.2011.11.006.CrossRefPubMed
Metadata
Title
High mortality of pneumonia in cirrhotic patients with ascites
Authors
Tsung-Hsing Hung
Chih-Wei Tseng
Yu-Hsi Hsieh
Kuo-Chih Tseng
Chih-Chun Tsai
Chen-Chi Tsai
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2013
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-13-25

Other articles of this Issue 1/2013

BMC Gastroenterology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.